GLS Archives - Spark Newswire

4 minute read

Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

April 5, 1:33 PM

Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 104% to $5.55 after the company announced it has been selected by the U.S. Department of Defense for a position on the multiple award Indefinite Delivery/Indefinite Quantity contract for high energy laser beams.

2 minute read

Earnings

Looking Into Gelesis Holdings’s Return On Capital Employed

By Benzinga Insights

March 29, 10:47 AM

Gelesis Holdings (NYSE:GLS) brought in sales totaling $2.63 million during Q4 according to data provided by Benzinga Pro.…

GLS

2 minute read

Earnings

Looking Into Gelesis Holdings’s Return On Capital Employed

By Benzinga Insights

March 29, 10:47 AM

Gelesis Holdings (NYSE:GLS) brought in sales totaling $2.63 million during Q4 according to data provided by Benzinga Pro.…

GLS

3 minute read

Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

March 20, 2:18 PM

Gainers

ABR

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

March 20, 9:06 AM

Gainers INVO Bioscience (NASDAQ:INVO) stock moved upwards by 77.7% to $0.96 during Monday’s pre-market session. The market value…

ALLR

31 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

March 15, 1:25 PM

On Wednesday, 479 stocks made new 52-week lows.

AAP

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

February 20, 5:31 PM

Gainers Owlet (NYSE:OWLT) shares rose 43.8% to $0.49 during Monday’s after-market session. At the close, Owlet’s trading volume…

AFIB

4 minute read

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

January 4, 2:17 PM

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.

AIM

9 minute read

FDA
News

PureTech Health Plc Provides Update On Progress Made Across Its Wholly Owned Programs And Founded Entities In 2022

By Benzinga Newsdesk

December 22, 5:42 AM

Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone).

AKLI